Nanobiotechnology and Nanomedicine Companies

 

Showing results 21 - 30 of 83 of companies in USA:

 
Combining the latest in nanotechnology and biotechnology, the company's Irys System with its nanovhannels allows to visualize the whole genome, capturing extremely long molecules at high resolution.
A bionanotech designer and maker of nanostructured chips, devices and systems for fast, comprehensive, and low-cost analysis of native state genomic, epigenomic and proteomic information with sensitivity at the single cell / single molecule level.
BioPAL provides products and methods to measure in vivo organ function and to track compounds-of-interest in in vivo systems. Products developed for neutron activation technology include nanocolloids for labeling, tracking and quantifying cells in in vivo models.
The company develops new treatments for cancer based on a portfolio of delivery technologies including liposomes, polymers and nanotechnologies.
Celera has a successful molecular diagnostics business and powerful genomic and proteomic discovery platforms that have identified and validated new drug targets and biomarkers that will advance the practice of Targeted Medicine.
Covaris, Inc. is a life science instrument company. Its proprietary instrument platform, based on patented Adaptive Focused Acoustic (AFA) technology brings unsurpassed speed and efficiency to biological and chemical sample preparation. The AFA process, based on shock wave physics, delivers controlled, precise and accurate energy to biological and chemical samples.
Creative Biolabs focuses on developing novel antibodies or equivalents with desired specificity and affinity for research, diagnostic, or therapeutic applications.
The Company is developing a pipeline of multifunctional, next-generation therapeutics, binding known anti-cancer agents to its patented colloidal gold tumor-targeting nanotechnology.
Delpor develops the next generation Drug Delivery Systems that improve the clinical and commercial value of drugs and biopharmaceuticals. The company also has developed a microfabricated nanopore device for the sustained release of therapeutic agents.
The company's NLP technology produces a generation of particles which retains the strength of the Dermazone Solutions' (SDMC) technologies, but includes the ability to produce particles of 60 nanometers to 150 nanometers which are optically clear. The use of this generation of lipid-based particle delivery system provides the ability to control the size of the final particle by controlling the number of NLPs used to assemble the finished particle. This system maintains very high loading capacity of passenger molecules and uses only safe, all natural ingredients to form both the NLPs and the final delivery system.